Healthcare Professionals
Please log in for special information and services

Product Details

Ocaliva® is indicated for the treatment of primary biliary cholangitis (also known to as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.

Intercept Pharma International Ltd. is the MA-Holder and AOP Orphan has the distribution right

Patient Information Leaflet Ocaliva® in Polish

Drug Facts

Active ingredient

Obeticholic acid